{"id":"risperidone-and-placebo-comparator","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Somnolence"},{"rate":"5-15%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This dual action helps to reduce symptoms of psychosis, such as hallucinations and delusions, by blocking the effects of dopamine and serotonin in the brain. Risperidone also has some effect on other neurotransmitter systems, including norepinephrine and acetylcholine.","oneSentence":"Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:22.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT04105231","phase":"PHASE2","title":"Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lone Baandrup","startDate":"2021-06-01","conditions":"Dual Diagnosis","enrollment":64},{"nctId":"NCT01625000","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":512},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT07060872","phase":"NA","title":"the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period.","status":"NOT_YET_RECRUITING","sponsor":"Shahid Sadoughi University of Medical Sciences and Health Services","startDate":"2025-07-07","conditions":"Age 3 to 7 Years, Mild Autism Spectrum, no Other Illness or Disorder","enrollment":82},{"nctId":"NCT05710237","phase":"PHASE2","title":"Does Psilocybin Require Psychedelic Effects to Treat Depression?","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-07-01","conditions":"Treatment-resistant Depression","enrollment":60},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT06838104","phase":"NA","title":"Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-05","conditions":"Schizophrenia Disorders, Psychotic Disorder","enrollment":76},{"nctId":"NCT04639960","phase":"NA","title":"Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome","status":"TERMINATED","sponsor":"University of Geneva, Switzerland","startDate":"2017-09-29","conditions":"22q11.2 Deletion Syndrome","enrollment":16},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06623227","phase":"NA","title":"Effect of Increasing Total Antioxidant Capacity in Autism Spectrum Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Rinvil Renaldi","startDate":"2024-09-28","conditions":"Autism Spectrum Disorder","enrollment":50},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT03055338","phase":"PHASE2","title":"An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-08","conditions":"Schizophrenia, Acute Episode","enrollment":224},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT05491720","phase":"PHASE1","title":"Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder","status":"COMPLETED","sponsor":"The National Brain Mapping Laboratory (NBML)","startDate":"2020-08-15","conditions":"Autism Spectrum Disorder","enrollment":45},{"nctId":"NCT04512066","phase":"PHASE2","title":"A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":287},{"nctId":"NCT03503318","phase":"PHASE3","title":"Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-04-27","conditions":"Schizophrenia","enrollment":544},{"nctId":"NCT04567524","phase":"PHASE2","title":"A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2020-08-13","conditions":"Schizophrenia Schizoaffective","enrollment":34},{"nctId":"NCT03893825","phase":"PHASE3","title":"A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-04-17","conditions":"Schizophrenia","enrollment":336},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01171937","phase":"PHASE2","title":"Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-09","conditions":"Autism","enrollment":41},{"nctId":"NCT03870880","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2017-08-25","conditions":"Schizophrenia","enrollment":215},{"nctId":"NCT03160521","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2017-06-02","conditions":"Acute Schizophrenia","enrollment":438},{"nctId":"NCT00698022","phase":"PHASE1","title":"A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2008-11","conditions":"Healthy","enrollment":76},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT00167154","phase":"PHASE3","title":"Risperidone and Suicidality in Major Depressive Disorder","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-06","conditions":"Depression","enrollment":30},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00221403","phase":"PHASE3","title":"Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT04587115","phase":"EARLY_PHASE1","title":"Reducing the Abuse Liability of Prescription Opioids","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-06-16","conditions":"Addiction","enrollment":15},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT02002832","phase":"PHASE3","title":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2013-12","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT02118688","phase":"PHASE4","title":"Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium","status":"WITHDRAWN","sponsor":"Rochester General Hospital","startDate":"2011-03","conditions":"Delirium, Agitation","enrollment":""},{"nctId":"NCT00148616","phase":"PHASE3","title":"Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia","status":"TERMINATED","sponsor":"M. Schaefer, MD","startDate":"2004-04","conditions":"Chronic Schizophrenia","enrollment":13},{"nctId":"NCT00148590","phase":"PHASE3","title":"Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia","status":"TERMINATED","sponsor":"M. Schaefer, MD","startDate":"2005-11","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT00694707","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06-30","conditions":"Schizophrenia","enrollment":732},{"nctId":"NCT03887754","phase":"PHASE2","title":"Therapeutic Issues for Autism","status":"COMPLETED","sponsor":"Minia University","startDate":"2016-01","conditions":"Autism Spectrum Disorder","enrollment":80},{"nctId":"NCT02456454","phase":"PHASE3","title":"Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2006-01","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT01516424","phase":"PHASE3","title":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2012-02","conditions":"Schizophrenia","enrollment":267},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01175135","phase":"PHASE2","title":"An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Schizophrenia","enrollment":259},{"nctId":"NCT01931059","phase":"NA","title":"Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"Imaging of the Brain and Antipsychotics, Neuronal Network Changes","enrollment":11},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT00799383","phase":"PHASE3","title":"Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia","status":"COMPLETED","sponsor":"Chadi A. Calarge","startDate":"2008-11","conditions":"Risperidone-induced Hyperprolactinemia","enrollment":47},{"nctId":"NCT00049946","phase":"PHASE2","title":"Schizophrenia Study In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-10","conditions":"Schizophrenia","enrollment":231},{"nctId":"NCT02535156","phase":"PHASE1, PHASE2","title":"Schizotypal Personality Disorder Risperidone","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2003-01","conditions":"Schizotypal Personality Disorder","enrollment":21},{"nctId":"NCT00796302","phase":"PHASE4","title":"Treatment of Severe Childhood Aggression (The TOSCA Study)","status":"COMPLETED","sponsor":"Michael Aman","startDate":"2008-08","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":168},{"nctId":"NCT02538081","phase":"PHASE1, PHASE2","title":"Nicotinic Receptors and Schizophrenia","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2015-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00385801","phase":"PHASE2","title":"Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-09","conditions":"Cocaine Dependence","enrollment":31},{"nctId":"NCT00435370","phase":"PHASE3","title":"Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-11","conditions":"Smoking Cessation, Schizophrenia","enrollment":179},{"nctId":"NCT01786239","phase":"NA","title":"Omega-3 Dietary Supplements in Schizophrenia","status":"COMPLETED","sponsor":"Delbert Robinson","startDate":"2013-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":50},{"nctId":"NCT01140620","phase":"PHASE4","title":"Effects of Ketamine and Risperidone on Cognition","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2010-06","conditions":"Healthy Volunteers, Schizophrenia","enrollment":87},{"nctId":"NCT00810667","phase":"PHASE2","title":"Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-11","conditions":"Schizophrenia, Cognition","enrollment":124},{"nctId":"NCT02019329","phase":"PHASE1","title":"A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Schizophrenia","enrollment":32},{"nctId":"NCT01708616","phase":"PHASE1","title":"A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT00158028","phase":"NA","title":"Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"1995-11","conditions":"Schizotypal Personality Disorder","enrollment":25},{"nctId":"NCT01524380","phase":"NA","title":"Ginkgo Biloba Extract for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2011-09","conditions":"Schizophrenia","enrollment":124},{"nctId":"NCT00686140","phase":"NA","title":"A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2006-06","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01391403","phase":"PHASE3","title":"Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2008-09","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT00439634","phase":"PHASE2","title":"Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Schizophrenia","enrollment":873},{"nctId":"NCT01977300","phase":"PHASE3","title":"Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01","conditions":"Bipolar I Disorder","enrollment":159},{"nctId":"NCT01624675","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2012-09","conditions":"Autistic Disorder in Children and Adolescents","enrollment":39},{"nctId":"NCT00133822","phase":"PHASE1, PHASE2","title":"Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2004-04","conditions":"Post-Traumatic Stress Disorders","enrollment":65},{"nctId":"NCT01770600","phase":"NA","title":"Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2010-04","conditions":"Impulsivity, Active Suicidal Ideation, Depression","enrollment":""},{"nctId":"NCT00103727","phase":"PHASE2","title":"Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Schizophrenia","enrollment":282},{"nctId":"NCT02202213","phase":"PHASE1","title":"Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT01813643","phase":"PHASE4","title":"A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"TERMINATED","sponsor":"Wei Hao","startDate":"2012-07","conditions":"Methamphetamine Dependence","enrollment":50},{"nctId":"NCT01450514","phase":"PHASE2","title":"POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia","status":"COMPLETED","sponsor":"PharmaNeuroBoost N.V.","startDate":"2012-03","conditions":"Chronic Schizophrenia, Schizoaffective Disorder","enrollment":7},{"nctId":"NCT00215241","phase":"PHASE2, PHASE3","title":"Risperidone Augmentation for PTSD","status":"COMPLETED","sponsor":"Duke University","startDate":"2004-04","conditions":"Post-Traumatic Stress Disorder","enrollment":80},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00576732","phase":"PHASE4","title":"A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Autistic Disorder, Autism","enrollment":96},{"nctId":"NCT00391222","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-11","conditions":"Bipolar Disorder","enrollment":585},{"nctId":"NCT00389493","phase":"NA","title":"Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-10","conditions":"Obsessive-Compulsive Disorder","enrollment":100},{"nctId":"NCT00005014","phase":"PHASE3","title":"Treatment of Autism in Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1997-10","conditions":"Autistic Disorder","enrollment":101},{"nctId":"NCT00563706","phase":"PHASE2","title":"Study Evaluating Vabicaserin in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12","conditions":"Schizophrenia","enrollment":199},{"nctId":"NCT01495156","phase":"PHASE4","title":"Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2011-09","conditions":"Bipolar I Disorder","enrollment":""},{"nctId":"NCT00132678","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-02","conditions":"Bipolar Disorder","enrollment":559},{"nctId":"NCT01189006","phase":"PHASE2, PHASE3","title":"Add-On Therapy to Risperidonein Schizophrenia","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2005-01","conditions":"Schizophrenia","enrollment":161},{"nctId":"NCT00300963","phase":"PHASE2","title":"Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Schizophrenia","enrollment":275},{"nctId":"NCT01284959","phase":"PHASE4","title":"Different Safety Profile of Risperidone and Paliperidone Extended-release","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2010-06","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT01423487","phase":"NA","title":"Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea","status":"WITHDRAWN","sponsor":"Central South University","startDate":"2011-08","conditions":"Weight Gain, Amenorrhea","enrollment":""},{"nctId":"NCT00794625","phase":"PHASE4","title":"Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)","status":"UNKNOWN","sponsor":"Joseph Blader","startDate":"2008-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":270},{"nctId":"NCT01556763","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2008-04","conditions":"Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases","enrollment":21},{"nctId":"NCT01272765","phase":"PHASE2","title":"Anti-psychotic Medication (Stable Dose) Weight Loss Study","status":"WITHDRAWN","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2012-03","conditions":"Obesity","enrollment":""},{"nctId":"NCT01272752","phase":"PHASE2","title":"Anti-psychotic Medication (New Use) Weight Loss Study","status":"WITHDRAWN","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2013-04","conditions":"Obesity","enrollment":""},{"nctId":"NCT00061802","phase":"PHASE4","title":"Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":225},{"nctId":"NCT00277654","phase":"PHASE3","title":"Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2004-02","conditions":"Bipolar Disorder, Anxiety Disorder","enrollment":111},{"nctId":"NCT00791232","phase":"PHASE1","title":"A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":113},{"nctId":"NCT00088075","phase":"PHASE3","title":"Investigate Risperidone for the Treatment of Schizophrenia in Adolescents","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-08","conditions":"Schizophrenia","enrollment":160},{"nctId":"NCT00236444","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-12","conditions":"Attention Deficit and Disruptive Behavior Disorders","enrollment":375},{"nctId":"NCT00076115","phase":"PHASE3","title":"Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-12","conditions":"Bipolar Disorder","enrollment":13},{"nctId":"NCT00086320","phase":"PHASE3","title":"A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":111},{"nctId":"NCT00287742","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2002-03","conditions":"Alzheimer's Disease, Dementia","enrollment":33},{"nctId":"NCT00094926","phase":"PHASE3","title":"A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Bipolar Disorder","enrollment":275},{"nctId":"NCT01259973","phase":"PHASE1","title":"Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2011-02","conditions":"Pharmacogenetics, Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Risperidone and placebo comparator","genericName":"Risperidone and placebo comparator","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. Used for Schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}